Skip to main content

Advertisement

Log in

Redefining cancer immunotherapy—optimization, personalization, and new predictive biomarkers: 4th Cancer Immunotherapy and Immunomonitoring (CITIM) meeting, April 27–30, 2015, Ljubljana, Slovenia

  • Meeting Report
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abbreviations

AFP:

Alpha fetoprotein

CRC:

Colorectal cancer

CTL:

Cytotoxic T lymphocyte

CTLA:

Cytolytic T lymphocyte-associated

DC:

Dendritic cell

GBM:

Glioblastoma multiformae

GC:

Glucocorticoids

GM-CSF:

Granulocyte–macrophage CSF

HCC:

Hepatocellular carcinoma

IDO:

Indoleamine 2,3-dioxygenase

IFITM:

Interferon-inducible transmembrane protein family

IFN-γ:

Interferon gamma

IL-1:

Interleukin 1

MAPK:

Mitogen-activated protein kinase

MDSC:

Myeloid-derived suppressor cell

MHC:

Major histocompatibility complex

MM:

Multiple myeloma

MMP:

Matrix metalloproteinases

MSC:

Mesenchymal stem cell

PBMC:

Peripheral blood mononuclear cell

PD-1:

Programmed death 1 receptor

PD-L1:

Programmed death ligand 1

RCC:

Renal cell carcinoma

SOCS3:

Suppressor of cytokine signaling-3

STAT:

Signal transducer and activator of transcription

TAA:

Tumor-associated antigen

TAM:

Tumor-associated macrophage

TAN:

Tumor-associated neutrophil

TCR:

T cell receptor for Ag

TEX:

Tumor-derived exosomes

TGF:

Transforming growth factor

TIL:

Tumor-infiltrating lymphocyte

TIMC:

Tumor-infiltrating myeloid cell

TLS:

Tertiary lymphoid structures

TME:

Tumor microenvironment

TNF:

Tumor necrosis factor

TRAIL:

TNF-related apoptosis-inducing

Treg:

Regulatory T cell

UCP2:

Uncoupling protein 2

Acknowledgments

We thank for generous support of the CITIM meeting: CTL (Cellular Technology Ltd), Europe GmbH, Bonn, Germany; GTCbio (Global Technology Community), Monrovia, CA, USA; Immatics Biotechnologies GmbH, Tübingen, Germany; PIVAC (Progress in Vaccination against Cancer); Springer Science + Business Media B.V.; Cancer Immunology and Immunotherapy (Springer); The Journal of Immunotoxicology (Taylor & Francis); eBioscience Affimetrix; CCNF (Cure Cancer Now Foundation), Los Angeles, CA, USA; SITC (Society for Immunotherapy of Cancer), Milwaukee, WI, USA; Immudex, Copenhagen, Denmark; MSD; Merck Sharp & Dohme, Sandoz Lek Pharmaceuticals d.d., Ljubljana, Slovenia; innovative drugs d.o.o., Ljubljana, Slovenia; Merck, d.o.o., Ljubljana, Slovenia; AstraZeneca, UK Limited, subsidiary in Ljubljana, Slovenia; Sanolabor, d.o.o., Ljubljana, Slovenia; Association of Radiology and Oncology, Ljubljana, Slovenia; Carl Zeiss d.o.o., Ljubljana, Slovenia; City Municipality of Ljubljana, Slovenia; Kemomed, d.o.o., Kranj, Slovenia.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Viktor Umansky.

Ethics declarations

Conflict of interest

The authors state no conflicts of interest.

Additional information

This meeting report is a summary of presentations from the Fourth International Conference on Cancer Immunotherapy and Immunomonitoring, CITIM 2015, published together with a series of Focussed Research Reviews based on lectures given at the conference.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aptsiauri, N., Jewett, A., Hurwitz, A.A. et al. Redefining cancer immunotherapy—optimization, personalization, and new predictive biomarkers: 4th Cancer Immunotherapy and Immunomonitoring (CITIM) meeting, April 27–30, 2015, Ljubljana, Slovenia. Cancer Immunol Immunother 65, 875–883 (2016). https://doi.org/10.1007/s00262-016-1795-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-016-1795-8

Keywords

Navigation